



Ottawa Hull K1A 0C9

(21)	(A1)	2,139,756
(86)		1993/07/07
(43)		1994/01/20

(51) Int.Cl. <sup>6</sup> A61K 39/39; A61K 39/29; A61K 39/145; A61K 38/19

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Use of GM-CSF as a Vaccine Adjuvant

(72) Bonnem, Eric M. - U.S.A. ;  
Chaudry, Imtiaz A. - U.S.A. ;  
Stupak, Elliot - U.S.A. ;

(71) Schering Corporation - U.S.A. ;

(30) (US) 07/910,399 1992/07/08

(57) 11 Claims



Notice: This application is as filed and may therefore contain an incomplete specification.



**USE OF GM-CSF AS A VACCINE ADJUVANT**

**Patent number:** CA2139756  
**Publication date:** 1994-01-20  
**Inventor:** BONNEM ERIC M (US); CHAUDRY IMTIAZ A (US);  
STUPAK ELLIOT (US)  
**Applicant:**  
**Classification:**  
- international: A61K39/39; A61K39/145; A61K38/19; A61K39/29  
- european: A61K39/145; A61K39/29B; A61K39/39  
**Application number:** CA19932139756 19930707  
**Priority number(s):** US19920910399 19920708; WO1993US06298  
19930707

**Also published as:**

 WO9401133 (A1)  
 EP0651656 (A1)

**Report a data error here**

**Abstract of CA2139756**

The present invention is a method for enhancing the immune response of a mammal to a vaccine comprising administering to such a mammal an effective amount of GM-CSF in conjunction with a vaccine. The present invention further provides for a pharmaceutical composition comprising an effective amount of GM-CSF, a natural, synthetic or recombinant antigen and a pharmaceutically acceptable carrier.

---

Data supplied from the **esp@cenet** database - Worldwide